Are SERMs safe and effective for the treatment of hypogonadism in men?
J Fam Pract
; 71(1): E18-E21, 2022 01.
Article
em En
| MEDLINE
| ID: mdl-35259334
YES. For both normal-weight and obese men with low testosterone levels and hypogonadal symptoms, selective estrogen receptor modulators (SERMs), such as clomiphene citrate (CC) and enclomiphene citrate (EC), appear to be effective and safe for improving serum testosterone levels (strength of recommendation [SOR]: C, disease-oriented outcomes from randomized controlled trials [RCTs] and cohort studies). Studies also show that symptom improvement is comparable to that with exogenous testosterone replacement and similar to eugonadal men (SOR: B, patient-oriented outcomes from retrospective cohort studies).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Enclomifeno
/
Hipogonadismo
Tipo de estudo:
Clinical_trials
/
Observational_studies
Limite:
Humans
/
Male
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article